**Supplementary Table 3. Incidence of organ failure according EASL criteria in the patients at presentation.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **All (n = 261)** | **cefotaxime(n = 87)** | **ceftriaxone(n = 87)** | **ciprofloxacin(n = 87)** |
| Liver failure (bilirubin ≥12 mg/dL) | 38 (14.6) | 12 (13.8) | 13 (14.9) | 13 (14.9) |
| Kidney failure (Cr ≥2.0 mg/dL) | 26 (10.0) | 11 (12.6) | 7 (8.0) | 8 (9.2) |
| Coagulation failure(INR ≥2.5) | 20 (7.7) | 4 (4.6) | 10 (11.5) | 6 (6.9) |
| Brain failure( ≥ WEST HAVEN grade 3) | 14 (5.4) | 4 (4.6) | 5 (5.7) | 5 (5.7) |
| Circulatory failure (vasopressin use for shock) | 8 (3.1) | 4 (4.6) | 2 (2.3) | 2 (2.3) |
| Respiratory failure | 4 (1.5) | 2 (2.3) | 1 (1.1) | 1 (1.1) |

Abbreviations: EASL, The European Association for the Study of Liver; INR, international normalized ratio